Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA withdrawing Rx laxative ANDAs

This article was originally published in The Tan Sheet

Executive Summary

FDA offers opportunities to firms marketing prescription laxatives containing polyethylene glycol 3350, which Schering-Plough has marketed OTC with MiraLax since late 2007, to contest the agency's proposal to withdraw approval for the Rx products. In an Oct. 24 Federal Register notice, FDA says in April 2007 it proposed withdrawing the abbreviated new drug applications for PEG 3350 held by Schwarz Pharma, Kali Laboratories, Nexgen Pharma, Coastal Pharmaceuticals and Teva Pharmaceutical Industries. After approving the MiraLax switch application in December 2006, FDA was required to remove prescription PEG 3350 drugs from the market because the Food, Drug and Cosmetic Act does not permit both Rx and OTC versions of the same product to be marketed at the same time, the agency says. None of the five manufacturers with an ANDA for prescription PEG 3350 have asked about changing their product labels to the approved OTC labeling or about voluntarily withdrawing the ANDAs. Each of the five firms has until Nov. 24 to ask FDA to schedule a hearing to contest the proposal. According to the notice, S-P's exclusivity for OTC MiraLax sales expired this month





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts